Dominican company based in Santo Domingo · We only ship within the Dominican Republic · No international shippingDominican Republic only · No international shipping
Analysis · Phase 3

Retatrutide and knee pain: what TRIUMPH-4 and TRIUMPH-1 showed at ACR 2026

At ACR Convergence 2026 (Orlando, November 6–11), two Phase 3 trials of retatrutide in adults with knee osteoarthritis pain and obesity or overweight were presented: TRIUMPH-4 and TRIUMPH-1. This is what the abstracts and Lilly's press release report, how to read the numbers, and what does not change: retatrutide remains an investigational molecule with no approval.

📖 7 min read 📅 Published 2026-11-10

What was presented at ACR 2026

ACR Convergence is the annual meeting of the American College of Rheumatology (ACR). The 2026 edition runs November 6–11 in Orlando, and it featured the results of two Eli Lilly Phase 3 trials of retatrutide in adults with knee osteoarthritis pain and obesity or overweight:

  • TRIUMPH-4, in a plenary session on November 8 (Abstract 0871; first author: Philip Conaghan, University of Leeds).
  • TRIUMPH-1 —its knee osteoarthritis cohort, called TRIUMPH-1-OA—, in a poster session on November 10 (Abstract 2573; first author: David Hunter, University of Sydney).

Lilly summarized both in a press release dated November 5, 2026. The topline TRIUMPH-4 figures had been public since December 2025. For TRIUMPH-1, the May 2026 release covered only the main trial and left the knee cohort data for later.

The two trials, side by side

 TRIUMPH-4TRIUMPH-1-OA
RegistryNCT05931367NCT05929066
DesignPhase 3, randomized, double-blind, placebo-controlledPhase 3, randomized, double-blind, placebo-controlled; cohort within TRIUMPH-1
Participants445574
Arms9 mg, 12 mg or placebo, weekly4 mg, 9 mg, 12 mg or placebo, weekly
Duration68 weeks80 weeks
Baseline WOMAC pain5.955.97
Mean baseline weight112.7 kg112.5 kg
Mean age · women55.2 years · 63.4%56.1 years · 75.8%

Source: abstracts 0871 and 2573, ACR Convergence 2026.

Entry criteria were the same in both: moderate-to-severe knee osteoarthritis pain —between 4 and 9 points on the WOMAC pain subscale— and a body mass index (BMI) of 27 kg/m² or higher. In TRIUMPH-4 the mean BMI was 40.4 kg/m².

What WOMAC measures

WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) is a questionnaire completed by the participant covering pain, stiffness and physical function. In these trials the pain subscale is expressed from 0 to 10, and participants started from an average close to 6.

The results: knee pain and weight

Mean change in the WOMAC pain subscale from baseline to the end of each trial, according to the abstracts presented at ACR and Lilly's press releases:

Trial · armChange in WOMAC pain (points)Percent change*
TRIUMPH-4 · 68 weeks
Retatrutide 9 mg−4.48−75.8%
Retatrutide 12 mg−4.41−74.3%
Placebo−2.43−40.3%
TRIUMPH-1-OA · 80 weeks
Retatrutide 4 mg−3.66not reported
Retatrutide 9 mg−4.19not reported
Retatrutide 12 mg−4.30not reported
Placebo−2.24not reported

*Percent change was not pre-specified: Lilly estimated it in a post hoc analysis. For TRIUMPH-1 the release gives a single figure, "up to 4.3 points (73.1%)," with no breakdown by arm. In both trials, p<0.001 versus placebo for every retatrutide arm. Sources: abstracts 0871 and 2573, ACR 2026; Lilly press releases of December 11, 2025 and November 5, 2026.

This is how the November 5 release sums it up: in TRIUMPH-4, retatrutide reduced knee osteoarthritis pain "by up to an average of 4.5 points (75.8%)" from an average baseline of 6.0; in TRIUMPH-1, "by up to 4.3 points (73.1%)" from a baseline of 6.0.

  • Participants with no knee pain at the end. According to Lilly, more than 1 in 8 retatrutide-treated patients in TRIUMPH-4 and more than 1 in 6 in TRIUMPH-1 finished the trial with no knee pain. For TRIUMPH-4 the company had given the breakdown in December 2025: 14.1% (9 mg) and 12.0% (12 mg), versus 4.2% on placebo, also in a post hoc analysis.
  • Weight. It was the other co-primary endpoint in TRIUMPH-4: −26.4% (9 mg) and −28.7% (12 mg), versus −2.1% on placebo, at 68 weeks. In TRIUMPH-1-OA the change in body weight ranged from −18.6% to −28.7% with retatrutide, versus −1.5% on placebo, at 80 weeks.
  • Physical function. Both abstracts report improvements in the WOMAC physical function subscale and a greater proportion of participants with reductions of 50% or more in pain and function versus placebo. The figures are in charts we do not reproduce here.

How to read these numbers

Four clarifications the headline leaves out:

  1. Placebo improved too. The placebo group dropped 2.43 points in TRIUMPH-4 and 2.24 in TRIUMPH-1-OA. The difference in means versus placebo was about 2 points with 9 mg and 12 mg (1.4 with 4 mg) on a 10-point scale; that is our own subtraction from the published figures, not a number from the release.
  2. "Up to" means the best arm. The 75.8% belongs to the 9 mg arm of TRIUMPH-4; the 12 mg arm came in at 74.3%. In that trial the two doses ended up practically equal (−4.48 and −4.41 points).
  3. The percentages are post hoc. What was pre-specified was the change in points. The percent reduction was estimated afterwards, as Lilly notes in a footnote, and the share of participants with no pain in TRIUMPH-4 also came from a post hoc analysis.
  4. There are two ways to count. The figures in the table use the efficacy estimand: what happens if the participant stays on treatment. With the treatment-regimen estimand, which includes those who discontinued, Lilly reported −4.0 points (9 mg) and −3.7 (12 mg) for TRIUMPH-4, versus −2.1 on placebo.

Two more limits. The trials measure the combined outcome: they do not separate how much of the change in pain tracks the change in weight and how much reflects another pathway. And what we cite here comes from conference abstracts and sponsor press releases, not from a full peer-reviewed paper.

Safety and tolerability

The two abstracts agree: the most common adverse events were gastrointestinal, mild to moderate; in TRIUMPH-4, mostly during dose escalation. In TRIUMPH-1-OA the 4 mg group reported fewer gastrointestinal events and fewer discontinuations due to adverse events.

The numeric detail available is for TRIUMPH-4, from Lilly's December 2025 release:

Adverse event (TRIUMPH-4)9 mg12 mgPlacebo
Nausea38.1%43.2%10.7%
Diarrhea34.7%33.1%13.4%
Constipation21.8%25.0%8.7%
Vomiting20.4%20.9%0.0%
Dysesthesia8.8%20.9%0.7%
Discontinuation due to adverse events12.2%18.2%4.0%

Source: Eli Lilly, topline results of the TRIUMPH-4 trial (December 11, 2025).

Two points worth not skipping:

  • Dysesthesia. Altered skin sensation appeared in one in five participants in the 12 mg arm. Lilly describes these events as generally mild and rarely a cause of discontinuation.
  • Discontinuations. Discontinuations due to adverse events reached 18.2% with 12 mg. According to the company, they correlated with baseline BMI and included participants who perceived they had lost too much weight; among those starting from a BMI of 35 or higher they were 8.8% and 12.1%, versus 4.8% on placebo.

The context: rheumatology and obesity

The knee trials are not the only thing Lilly brought to ACR 2026. Scheduled for November 11 is the presentation of TOGETHER-PsA, a Phase 3b trial that combined two already-approved medicines —ixekizumab (Taltz) and tirzepatide (Zepbound)— in adults with psoriatic arthritis and obesity, or overweight with at least one weight-related comorbidity. At week 52, 43.7% of those who received the combination achieved an ACR50 response, versus 15.7% with ixekizumab alone. Lilly notes that the week-52 analyses are exploratory and not controlled for multiplicity.

The common thread, according to the company, is studying what happens when a rheumatologic condition and obesity are addressed together. About 80% of people with knee osteoarthritis have obesity or overweight, per the references cited in the release.

Regulatory status and what it means for research

Retatrutide is not approved by any regulatory agency. In the same release, Lilly describes it as an investigational molecule that cannot be legally sold or marketed for human use, and lists what it is studying in Phase 3: obesity and overweight, type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease.

Three things these trials do not say:

  • They do not describe research material. The results correspond to Lilly's investigational product, administered inside clinical trials under medical supervision. They cannot be extrapolated to any other material, including ours.
  • They do not make retatrutide a treatment for knee pain. Today its only authorized use in people is inside clinical trials.
  • They do not replace verification. Outside a trial, the identity and purity of a compound are only known through independent analysis. We cover the study that measured the gap between unverified sources and the trials in Black-Market Retatrutide vs clinical trials.

At Renova, retatrutide is offered only as a reference material for laboratory research (RUO): research use only, not for human or veterinary consumption. This article makes no efficacy claims of its own: every figure comes from conference abstracts or sponsor press releases and is attributed to its source. What we do publish is the characterization of the material: the Janoshik certificates of analysis (HPLC + mass spectrometry) are at /en/coa/. We review the rest of the Phase 3 program in Retatrutide in Phase 3: What TRIUMPH-2 Showed.

Sources

Related products

⚠ Research use only. Not for human or veterinary consumption. Not medical advice. Retatrutide is a compound in clinical research, not approved for human use. The data cited come from conference abstracts and press releases from the trials' sponsor, and are presented for informational purposes.

Your Order

Your cart is empty